Feasibility of initial treatment in elderly patients with ovarian cancer in Japan: a retrospective study
The purpose of this study was to evaluate the real world situation and clarify the problem in initial treatment for elderly patients with ovarian cancer in Japan.
We used the ovarian cancer database, containing all patients diagnosed and treated with International Federation of Gynecology and Obstetrics Stage I–IV ovarian cancer at the National Cancer Center Hospital in Japan from June 2008 to April 2013. Patients were stratified into two groups based on age: an elderly group, aged 70 years or older, and a younger group, aged below 70 years. We retrospectively assessed the rate of receiving standard therapy, and the feasibility and safety of chemotherapy compared with younger patients.
In total, 244 patients (elderly group, 36 patients; younger group, 208 patients) were analyzed. A significantly lower proportion of elderly patients than younger patients received standard therapy (15.7% vs. 32.5%, p = 0.026). Even for the elderly group, 95% patients underwent surgery in our institution. Conversely the rate of patients receiving nonstandard chemotherapy in the elderly group was significantly higher than in the younger group (30.5% vs. 9.6%, p = 0.01).
This study clarified the type of treatment being performed in the field, and the proportion of elderly ovarian cancer patients receiving standard therapy compared with younger patients in Japan. In addition, the actual situation of elderly patients in Japan might be different from that in Western countries. We need to evaluate the appropriate treatment for elderly patients in Japan.
KeywordsElderly patients Ovarian cancer Standard therapy Relative dose intensity Feasibility
We thank Colleen Elso, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript. We would like to express our sincere thanks to all patients and investigators. The authors would like to thank Dr. Kan Yonemori, and Mr. Hiroyuki Terakado for supporting to make manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
- 1.Katsumata N, Yasuda M, Takahashi F et al (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698):(9698):1331–1338. https://doi.org/10.1016/S0140-6736(09)61157-0 CrossRefGoogle Scholar
- 6.Tredan O, Geay JF, Touzet S et al (2007) Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Ann Oncol 18(2):256–262. https://doi.org/10.1093/annonc/mdl400 CrossRefGoogle Scholar
- 10.Pignata S, Breda E, Scambia G et al (2008) A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A multicentre Italian trial in ovarian cancer (MITO-5) study. Crit Rev Oncol/Hematol 66(3):229–236. https://doi.org/10.1016/j.critrevonc.2007.12.005 CrossRefGoogle Scholar
- 11.Pignata S, Scambia G, Katsaros D et al (2014) Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15(4):396–405. https://doi.org/10.1016/S1470-2045(14)70049-X CrossRefGoogle Scholar
- 13.Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines (2004) Int J Clin Oncol 9(Suppl 3):1–82Google Scholar
- 17.Rauh-Hain JA, Melamed A, Wright A et al (2017) Overall survival following neoadjuvant chemotherapy vs primary cytoreductive surgery in women with epithelial ovarian cancer: analysis of the National Cancer Database. JAMA Oncol 3(1):76–82. https://doi.org/10.1001/jamaoncol.2016.4411 CrossRefGoogle Scholar
- 18.Katsumata N, Yasuda M, Isonishi S et al (2013) Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 14(10):1020–1026. https://doi.org/10.1016/S1470-2045(13)70363-2 CrossRefGoogle Scholar
- 22.Pignata S, Scambia G, Ferrandina G et al (2011) Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol 29(27):3628–3635. https://doi.org/10.1200/JCO.2010.33.8566 CrossRefGoogle Scholar
- 23.Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28(20):3323–3329. https://doi.org/10.1200/JCO.2009.25.7519 CrossRefGoogle Scholar